Endothelial cell dysfunction and cytoskeletal changes associated with repression of p16 INK4a during immortalization

Oncogene

Volumn 31, Issue 46, 2012, Pages 4815-4827

  Kan, C Y ^a   Wen, V W ^a   Pasquier, E ^a   Jankowski, K ^a   Chang, M ^a   Richards, L A ^a   Kavallaris, M ^a,b   MacKenzie, K L ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

cytoskeleton; Endothelial cell; immortalization; morphogenesis; p16INK4a; TERT

Indexed keywords

ALPHA TROPOMYOSIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; SMALL INTERFERING RNA; TELOMERASE REVERSE TRANSCRIPTASE; VIMENTIN;

AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL IMMORTALIZATION; CELL MOTILITY; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; CYTOSKELETON; ENDOTHELIUM CELL; ENZYME INACTIVATION; ENZYME REPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

ACTINS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYTOSKELETAL PROTEINS; CYTOSKELETON; ENDOTHELIAL CELLS; HUMANS; PROTEOMICS; TELOMERASE; TROPOMYOSIN; VIMENTIN;

EID: 84869505868     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.645     Document Type: Article

References (63)

1. Bell CD. Endothelial cell tumors. Microsc Res Tech 2003; 60:165-170. (Pubitemid 36125704)
2. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol [Research Support, Non-US Gov't; Review] 2010; 11:983-991.
3. Tannapfel A, Weihrauch M, Benicke M, Uhlmann D, Hauss J, Wrbitzky R et al. p16INK4A-alterations in primary angiosarcoma of the liver. J Hepatol 2001; 35:62-67.
4. Weihrauch M, Markwarth A, Lehnert G, Wittekind C, Wrbitzky R, Tannapfel A. Abnormalities of the ARF-p53 pathway in primary angiosarcomas of the liver. Hum Pathol 2002; 33:884-892.
5. 1 arrest, polyploidization and senescence-associated apoptosis. Exp Gerontol 2001; 36:1327-1347. (Pubitemid 32707871)
6. Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature [Research Support, Non-US Gov't; Research Support, US Gov't, PHS] 1993; 366:704-707. (Pubitemid 24036021)
7. Spike BT, Dirlam A, Dibling BC, Marvin J, Williams BO, Jacks T et al. The Rb tumor suppressor is required for stress erythropoiesis. EMBO J [Research Support, Non-US Gov't] 2004; 23:4319-4329. (Pubitemid 39546169)
8. Milyavsky M, Shats I, Cholostoy A, Brosh R, Buganim Y, Weisz L et al. Inactivation of myocardin and p16 during malignant transformation contributes to a differentiation defect. Cancer Cell 2007; 11:133-146. (Pubitemid 46209846)
9. Hernando E, Nahle Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M et al. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430:797-802. (Pubitemid 39071352)
10. Urashima M, Teoh G, Akiyama M, Yuza Y, Anderson KC, Maekawa K. Restoration of p16INK4A protein induces myogenic differentiation in RD rhabdomyosarcoma cells. Br J Cancer [Research Support, Non-US Gov't] 1999; 79:1032-1036. (Pubitemid 29087871)
11. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell [Research Support, NIH, Extramural; Review] 2011; 144:646-674.
12. Hsiao R, Sharma HW, Ramakrishnan S, Keith E, Narayanan R. Telomerase activity in normal human endothelial cells. Anticancer Res 1997; 17:827-832. (Pubitemid 27182866)
13. MacKenzie KL, Franco S, Naiyer AJ, May C, Sadelain M, Rafii S et al. Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40T antigen and oncogenic N-ras. Oncogene 2002; 21:4200-4211. (Pubitemid 34753826)
14. Yang J, Chang E, Cherry AM, Bangs CD, Oei Y, Bodnar A et al. Human endothelial cell life extension by telomerase expression. J Biol Chem [Research Support, Non-US Gov't; Research Support, US Gov't, PHS] 1999; 274:26141-26148.
15. Chang E, Harley CB. Telomere length and replicative aging in human vascular tissues. Proc Natl Acad Sci USA 1995; 92:11190-11194.
16. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T et al. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426:194-198. (Pubitemid 37442589)
17. Alcorta DA, Xiong Y, Phelps D, Hannon G, Beach D, Barrett JC. Involvement of the cyclin-dependent kinase inhibitor p16(INK4a) in replicative senescence of normal human fibroblasts. Proc Natl Acad Sci USA 1996; 93:13742-13747. (Pubitemid 26424190)
18. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996; 16:859-867.
19. Jacobs JJ, de Lange T. Significant role for p16INK4a in p53-independent telomere-directed senescence. Curr Biol 2004; 14:2302-2308. (Pubitemid 40033370)
20. Crawford YG, Gauthier ML, Joubel A, Mantei K, Kozakiewicz K, Afshari CA et al. Histologically normal human mammary epithelia with silenced p16(INK4a) overexpress COX-2, promoting a premalignant program. Cancer Cell [Research Support, Non-US Gov't; Research Support, US Gov't, Non-PHS; Research Support, US Gov't, PHS] 2004; 5:263-273. (Pubitemid 38402118)
21. Romanov SR, Kozakiewicz BK, Holst CR, Stampfer MR, Haupt LM, Tlsty TD. Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes. Nature 2001; 409:633-637. (Pubitemid 32154817)
22. Soler D, Genesca A, Arnedo G, Egozcue J, Tusell L. Telomere dysfunction drives chromosomal instability in human mammary epithelial cells. Genes Chromosomes Cancer 2005; 44:339-350. (Pubitemid 41476785)
23. Venetsanakos E, Mirza A, Fanton C, Romanov SR, Tlsty T, McMahon M. Induction of tubulogenesis in telomerase-immortalized human microvascular endothelial cells by glioblastoma cells. Exp Cell Res 2002; 273:21-33.
24. O'Hare MJ, Bond J, Clarke C, Takeuchi Y, Atherton AJ, Berry C et al. Conditional immortalization of freshly isolated human mammary fibroblasts and endothelial cells. Proc Natl Acad Sci USA 2001; 98:646-651. (Pubitemid 32105097)
25. Wen VW, Wu K, Baksh S, Hinshelwood RA, Lock RB, Clark SJ et al. Telomere-driven karyotypic complexity concurs with p16INK4a inactivation in TP53-competent immortal endothelial cells. Cancer Res 2006; 66:10691-10700. (Pubitemid 44876964)
26. Gil-Benso R, Lopez-Gines C, Soriano P, Almenar S, Vazquez C, Llombart-Bosch A. Cytogenetic study of angiosarcoma of the breast. Genes Chromosomes Cancer [Case Reports] 1994; 10:210-212. (Pubitemid 24198761)
27. Kindblom LG, Stenman G, Angervall L. Morphological and cytogenetic studies of angiosarcoma in Stewart-Treves syndrome. Virchows Arch A Pathol Anat Histopathol [Case Reports; Research Support, Non-US Gov't] 1991; 419:439-445.
28. Mandahl N, Jin YS, Heim S, Willen H, Wennerberg J, Biorklund A et al. Trisomy 5 and loss of the Y chromosome as the sole cytogenetic anomalies in a cavernous hemangioma/angiosarcoma. Genes Chromosomes Cancer 1990; 1:315-316. (Pubitemid 20218518)
29. Schuborg C, Mertens F, Rydholm A, Brosjo O, Dictor M, Mitelman F et al. Cytogenetic analysis of four angiosarcomas from deep and superficial soft tissue. Cancer Genet Cytogenet 1998; 100:52-56. (Pubitemid 128766343)
30. Zu Y, Perle MA, Yan Z, Liu J, Kumar A, Waisman J. Chromosomal abnormalities and p53 gene mutation in a cardiac angiosarcoma. Appl Immunohistochem Mol Morphol [Case Reports] 2001; 9:24-28. (Pubitemid 32179106)
31. Baumhoer D, Gunawan B, Becker H, Fuzesi L. Comparative genomic hybridization in four angiosarcomas of the female breast. Gynecol Oncol 2005; 97:348-352. (Pubitemid 40614874)
32. Alhaja E, Adan J, Pagan R, Mitjans F, Cascallo M, Rodriguez M et al. Anti-migratory and anti-angiogenic effect of p16: a novel localization at membrane ruffles and lamellipodia in endothelial cells. Angiogenesis [Research Support, Non-US Gov't] 2004; 7:323-333. (Pubitemid 40767934)
33. Chen J, Huang X, Halicka D, Brodsky S, Avram A, Eskander J et al. Contribution of p16INK4a and p21CIP1 pathways to induction of premature senescence of human endothelial cells: permissive role of p53. Am J Physiol Heart Circ Physiol 2006; 290: H1575-H1586.
34. Minamino T, Miyauchi H, Yoshida T, Ishida Y, Yoshida H, Komuro I. Endothelial cell senescence in human atherosclerosis: role of telomere in endothelial dysfunction. Circulation 2002; 105:1541-1544. (Pubitemid 34297628)
35. Minamino T, Miyauchi H, Yoshida T, Tateno K, Komuro I. The role of vascular cell senescence in atherosclerosis: antisenescence as a novel therapeutic strategy for vascular aging. Curr Vasc Pharmacol 2004; 2:141-148. (Pubitemid 38855022)
36. Chinnam M, Goodrich DW. RB1, development, and cancer. Curr Top Dev Biol [Research Support, NIH, Extramural; Review] 2011; 94:129-169.
37. Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ Res [Research Support, US Gov't, Non-PHS; Review] 2007; 100:782-794. (Pubitemid 46555683)
38. Ivaska J, Pallari HM, Nevo J, Eriksson JE. Novel functions of vimentin in cell adhesion, migration, and signaling. Exp Cell Res [Review] 2007; 313:2050-2062. (Pubitemid 46842979)
39. Eckes B, Dogic D, Colucci-Guyon E, Wang N, Maniotis A, Ingber D et al. Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J Cell Sci [Research Support, Non-US Gov't; Research Support, US Gov't, Non-PHS; Research Support, US Gov't, PHS] 1998; 111 (Pt 13):1897-1907. (Pubitemid 28370534)
40. Eriksson JE, He T, Trejo-Skalli AV, Harmala-Brasken AS, Hellman J, Chou YH et al. Specific in vivo phosphorylation sites determine the assembly dynamics of vimentin intermediate filaments. J Cell Sci [Research Support, Non-US Gov't] 2004; 117(Pt 6):919-932. (Pubitemid 38386949)
41. Valgeirsdottir S, Claesson-Welsh L, Bongcam-Rudloff E, Hellman U, Westermark B, Heldin CH. PDGF induces reorganization of vimentin filaments. J Cell Sci 1998; 111(Pt 14):1973-1980. (Pubitemid 28391063)
42. Nylund R, Leszczynski D. Proteomics analysis of human endothelial cell line EA.hy926 after exposure to GSM 900 radiation. Proteomics [Research Support, Non-US Gov't] 2004; 4:1359-1365. (Pubitemid 38648024)
43. Wang E. Are cross-bridging structures involved in the bundle formation of intermediate filaments and the decrease in locomotion that accompany cell aging? J Cell Biol [Research Support, US Gov't, PHS] 1985; 100:1466-1473. (Pubitemid 15098021)
44. Nishio K, Inoue A, Qiao S, Kondo H, Mimura A. Senescence and cytoskeleton: overproduction of vimentin induces senescent-like morphology in human fibroblasts. Histochem Cell Biol [Research Support, Non-US Gov't] 2001; 116:321-327. (Pubitemid 32972326)
45. Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol [Review] 2008; 97:321-329. (Pubitemid 351358580)
46. Gunning PW, Schevzov G, Kee AJ, Hardeman EC. Tropomyosin isoforms: divining rods for actin cytoskeleton function. Trends Cell Biol [Research Support, Non-US Gov't; Review] 2005; 15:333-341. (Pubitemid 40805330)
47. Houle F, Poirier A, Dumaresq J, Huot J. DAP kinase mediates the phosphorylation of tropomyosin-1 downstream of the ERK pathway, which regulates the formation of stress fibers in response to oxidative stress. J Cell Sci 2007; 120(Pt 20):3666-3677. (Pubitemid 350120958)
48. Huang B, Chen SC, Wang DL. Shear flow increases S-nitrosylation of proteins in endothelial cells. Cardiovasc Res [Research Support, Non-US Gov't] 2009; 83:536-546.
49. Prasad GL, Fuldner RA, Cooper HL. Expression of transduced tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene. Proc Natl Acad Sci USA [In Vitro] 1993; 90:7039-7043. (Pubitemid 23222384)
50. Hendricks M, Weintraub H. Tropomyosin is decreased in transformed cells. Proc Natl Acad Sci USA [Research Support, US Gov't, PHS] 1981; 78:5633-5637. (Pubitemid 12245204)
51. Franzen B, Linder S, Uryu K, Alaiya AA, Hirano T, Kato H et al. Expression of tropomyosin isoforms in benign and malignant human breast lesions. Br J Cancer [Comparative Study; Research Support, Non-US Gov't] 1996; 73:909-913. (Pubitemid 26110162)
52. Bhattacharya B, Prasad GL, Valverius EM, Salomon DS, Cooper HL. Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res [In Vitro] 1990; 50:2105-2112. (Pubitemid 20115084)
53. Hughes JA, Cooke-Yarborough CM, Chadwick NC, Schevzov G, Arbuckle SM, Gunning P et al. High-molecular-weight tropomyosins localize to the contractile rings of dividing CNS cells but are absent from malignant pediatric and adult CNS tumors. Glia [Research Support, Non-US Gov't] 2003; 42:25-35. (Pubitemid 36427418)
54. Wang FL, Wang Y, Wong WK, Liu Y, Addivinola FJ, Liang P et al. Two differentially expressed genes in normal human prostate tissue and in carcinoma. Cancer Res [Research Support, Non-US Gov't] 1996; 56:3634-3637. (Pubitemid 26272002)
55. Zheng Q, Safina A, Bakin AV. Role of high-molecular weight tropomyosins in TGF-beta-mediated control of cell motility. Int J Cancer [Research Support, NIH, Extramural; Research Support, US Gov't, Non-PHS] 2008; 122:78-90. (Pubitemid 350209981)
56. MacDonald NJ, Shivers WY, Narum DL, Plum SM, Wingard JN, Fuhrmann SR et al. Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 2001; 276:25190-25196.
57. Zhang JC, Donate F, Qi X, Ziats NP, Juarez JC, Mazar AP et al. The antiangiogenic activity of cleaved high molecular weight kininogen is mediated through binding to endothelial cell tropomyosin. Proc Natl Acad Sci USA [Research Support, US Gov't, Non-PHS; Research Support, US Gov't, PHS] 2002; 99:12224-12229.
58. Huang S, Chen CS, Ingber DE. Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. Mol Biol Cell [Research Support, Non-US Gov't; Research Support, US Gov't, PHS] 1998; 9:3179-3193. (Pubitemid 28516630)
59. Ling X, Li F. Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. Biotechniques [Comparative Study; Evaluation Studies; Research Support, Non-US Gov't; Validation Studies] 2004; 36:450-454; 6-60.
60. Pasquier E, Sinnappan S, Munoz MA, Kavallaris M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Mol Cancer Ther [Research Support, Non-US Gov't] 2010; 9:1408-1418.
61. Kouvroukoglou S, Dee KC, Bizios R, McIntire LV, Zygourakis K. Endothelial cell migration on surfaces modified with immobilized adhesive peptides. Biomaterials [Research Support, US Gov't, Non-PHS] 2000; 21:1725-1733. (Pubitemid 30365035)
62. Verrills NM, Liem NL, Liaw TY, Hood BD, Lock RB, Kavallaris M. Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study. Proteomics 2006; 6:1681-1694.
63. Schevzov G, Vrhovski B, Bryce NS, Elmir S, Qiu MR, O'Neill G M et al. Tissue-specific tropomyosin isoform composition. J Histochem Cytochem [Research Support, Non-US Gov't] 2005; 53:557-570. (Pubitemid 40593969)